ST LOUIS (MD Consult) - On October 22, 2010, Warner Chilcott announced that the US Food and Drug Administration (FDA) has approved Lo Loestrin FE (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets) for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

According to the manufacturer, Lo Loestrin FE offers women the lowest dosage of estrogen (10 μ) of any oral contraceptive currently available in the US market.

Cigarette smoking increases the risk of serious cardiovascular events from the use of combination oral contraceptives. This risk increases with age, particularly in women older than 35 years, and with the number of cigarettes smoked. Combination oral contraceptives should not be taken by women older than 35 years who smoke.

Warner Chilcott anticipates the commercial launch of Lo Loestrin FE in early 2011.

圣路易斯(MD Consult)——2010年10月22日，华纳奇考特公司宣称，美国食品药品管理局(FDA)已批准 Lo Loestrin FE(醋酸炔诺酮和炔雌醇片，炔雌醇片和富马酸亚铁片)用于选用口服避孕药避孕的女性。

生产商表示，Lo Loestrin FE的雌激素含量(10 μ)低于目前美国市场上的任何口服避孕药。

吸烟可使应用复方口服避孕药后发生严重心血管事件的风险增加。该风险随着年龄的增加而上升，尤其是35岁以上的女性，而且还随着吸烟数量的增加而上升。35岁以上的吸烟女性不应使用复方口服避孕药。

华纳奇考特公司预计Lo Loestrin FE将于2011年初上市。